Skip to content

International Liver Surgery Outcomes Study

International Study on the Outcomes of Liver Surgery - LiverGroup.Org

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03768141
Acronym
LiverGroup
Enrollment
2500
Registered
2018-12-07
Start date
2019-01-01
Completion date
2020-03-31
Last updated
2020-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Diseases

Keywords

Liver, Surgery, Outcomes, Snapshot, Collaborative, International

Brief summary

This study was to designed to measure the true worldwide practice of liver surgery and associated outcomes by recruiting multiple international centres, committing to consecutive patient registration per surgeon and undergo rigorous data validation. It is hoped that these data will provide a more appropriate guide to inform surgeons and patients to assess which level of complexity should be routinely offered for high tumour burden and anatomically difficult scenarios.

Detailed description

Liver surgery was associated with at least 10% mortality in the 1970's. The safety of liver surgery has dramatically improved since with a mortality of now around 1-2%. Individual centres postulate that a perioperative mortality close to 0% should be the standard of major liver resection. Despite these claims, epidemiological studies showed a mortality rate of 6%. Outcomes in liver surgery are likely influenced by indications, complexity, centre and surgeon skills, equipment, centre and surgeon experience. The aim of LiverGroup.org is to develop an international data set on the outcomes of liver resections among a large number of international surgeons. The 'collaborative' model for 'snapshot' clinical audit is now well established and such research is a novel approach for assessing current practice in a short period of time. The primary objective of the study is to provide a verified record of the true perioperative morbidity and mortality of a representative set of liver surgeons worldwide in 2019. Secondary objectives include risk factors for mortality and morbidity using multivariable regression models. Any surgeon performing liver resections is eligible to participate in LiverGroup.org. All consecutive cases will be included and there are no minimum patient numbers per centre. Liver transplantation is excluded. There will be 3 months of prospective patient enrolment and 3 months follow up within the 12-month frame, January to December 2019. All liver resections, all indications, as well as all co-morbidities will be included. Liver transplantation, imaging-guided ablations and liver biopsies are excluded.

Interventions

PROCEDURELiver surgery

All indications (including benign and living donor resections), all co-morbidities, open, laparoscopic or robotic, single wedge resections to extended liver resections, single or two-stage hepatectomies, procedures with liver volume enhancement such as portal vein embolization (PVE), portal vein ligation (PVL), Associating Liver Partition and Portal vein Ligation for Staged hepatectomy (ALPPS), resections involving cold perfusion (ex-situ and ante-situ)

Sponsors

Hospital Miguel Servet
CollaboratorOTHER
Royal Free Hospital NHS Foundation Trust
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All indications (including benign and living donor resections) * All co-morbidities * Open, laparoscopic or robotic * Single wedge resections to extended liver resections * Single or two-stage hepatectomies * Procedures with liver volume enhancement such as PVE, PVL, ALPPS. * Resections involving cold perfusion (ex-situ and ante-situ) * There are no

Exclusion criteria

as related to indication, age or comorbidities.

Design outcomes

Primary

MeasureTime frameDescription
Mortality rateFrom operation until 90 days postoperativelyDeath

Secondary

MeasureTime frameDescription
Complication rateFrom operation until 90 days postoperativelyPostoperative complications according the the Clavien-Dindo classification, the liver Failure, Ascites, Bile leakage, Infection, Bleeding (FABIB) liver specific classification, as well as the novel Comprehensive Complications Index® (CCI® ).
Liver failure rateFrom operation until 90 days postoperativePosthepatectomy liver failure will be assessed according to the FABIB Classification, the International Study Group of Liver Surgery (ISGLS) criteria as well as the 50-50 criteria up to 90 days postoperatively.
Hospital stayFrom operation until discharge from the hospital or up to 90 days postoperatively.The length of hospital stay is defined as the duration of hospitalization from the day of the operation until the day of discharge from the hospital.
Re-hospitalisation rateFrom operation until 90 days postoperativelyReadmission to any hospital

Countries

Spain, United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026